全球非專利藥品市場：2009年∼2024年 是由出版商Visiongain在2009年08月所出版的。
這份英文市場調查報告書包含124 pages 價格從美金2331起跳。
由於全球廉價藥物需求高漲，非專利藥品市場近年來快速成長。自2009年起的5年內主要藥物將面臨專利到期的狀況，非專利藥品市場將可望更加大幅成長。
本報告書內容包括：全球非專利藥品市場的銷售金額預測及國別市場定性、定量分析、特別是美國、歐洲、日本、中國、印度、俄羅斯等市場在2024年之前的預測。內容綱要摘記如下： 封面圖片：  第1章 實施概要
第2章 全球非專利藥品市場概要
- 非專利藥品介紹
- 須常保新鮮
- 全球藥品市場的成長極限
- 品牌藥
- 美國的規範
- 歐洲的規範
- 日本的規範
- 授權
- 非專利藥品：概要
第3章 全球非專利藥品市場預測：2009年∼2024年
- 非專利藥品vs品牌藥
- 2009年至2024年的銷售金額預測
- 暢銷藥品的專利失效
- 目前金融危機的影響
- 專利期限：2009年至2014年
- 大型製藥公司進入非專利藥品市場
- 地區別市場
- 治療領域
第4章 美國非專利藥品市場：2009年∼2024年
- 現在的市場分析
- 銷售金額預測：2009年至2024年
- 市場滲透度會達飽和狀態嗎？
- 消費者的接受度
- ANDA庫存
- 市場佔有率減少
- 規範環境
- 結論
第5章 歐洲非專利藥品市場：2009年∼2024年
- 現在的市場分析
- 銷售金額預測：2009年至2024年
- 德國非專利藥品市場
- 法國非專利藥品市場
- 英國非專利藥品市場
- 西班牙非專利藥品市場
- 義大利非專利藥品市場
- 結論
第6章 日本非專利藥品市場：2009年∼2024年
- 現在的市場分析
- 銷售金額預測：2009年∼2024年
- 規範環境
- 處方者的態度是主要的阻礙
- 合併及收購
- 結論
第7章 新興國家非專利藥品市場：2009年∼2024年
第8章 主要企業
- Teva Pharmaceutical Industries
- Novartis' Sandoz
- Mylan Inc
- Watson Pharmaceuticals
- Ratiopharm
第9章 促進及阻礙市場發展因素
第10章 專家觀點
第11章 結論
圖表
Abstract
The generic pharmaceuticals sector has been expanding strongly in recent years
as the need for cheaper medicines worldwide has increased. The next five years
from 2009 will see more leading drugs going off patent, thus increasing
opportunities for generics producers. Regulations favouring generic products
give cause for optimism in the generics sector, while still leaving scope for
novel branded drugs. We predict that total revenues in the generics market
will continue to increase in the years ahead.
Major players have been moving into the generic drugs market - spearheaded by
leading pharma companies and specialist pharma organisations. Established
generics companies, such as Teva, are increasing in commercial prominence and
international reach. There are many rising challengers in developed and
developing countries, inspired by patent expiry on major drugs. What will be
the main challenges and the main opportunities in this market from 2009
onwards? Our new report, World Generics Market 2009-2024, investigates such
questions in depth, providing you with the information that you need.
This report reveals forecasted sales in the world generics market and in
leading national markets, providing detailed quantitative and qualitative
data. In particular, World Generics Market 2009-2024 includes generics market
forecasts for:
- The US
- Europe (with special focus on Germany, France, the UK, Italy and Spain)
- Japan
- China
- India
- Russia.
Our report also gives in-depth profiles of the five leading generic
manufacturers: Teva, Sandoz, Mylan, Watson and Ratiopharm.
Comprehensive analysis of the global generics sector
World Generics Market 2009-2024 examines that sector critically, through a
comprehensive review of information sources. This report provides detailed
sales forecasts, discussions of developments and analyses of commercial
drivers and restraints, including a SWOT analysis. There are 61 tables and
figures and a full interview with an expert in the sector. The result is a
comprehensive market- and industry-centred report, with detailed analyses and
informed opinion to benefit your work.
Why you should buy World Generics Market 2009-2024
In this report you will receive the following benefits in particular:
- You will receive an appraisal of the current world generics market
- You will receive analyses of the potential value of the world generics
market, including detailed revenue forecasts from 2009 to 2024
- You will receive analyses of the most-promising areas for generic drug
development and marketing
- You will receive forecasts for principal geographical markets, especially
those with high growth potential
- You will examine strengths and weaknesses of the worldwide generics sector
from 2009 onwards, especially commercial drivers and restraints
- You will discover expert opinion from our industry survey.
Table of Contents
1 Executive Summary
- 1.1 Aims of This Report
- 1.2 Chapter Overview
2 Overview of the World Generics Market
- 2.1 Generic Drugs: An Introduction
- 2.1.1 Authorised, Branded and True Generics
- 2.2 Evergreening
- 2.3 Limited Growth in the World Pharmaceutical Market
- 2.4 Branded Pharmaceuticals: Is the Business Model Crumbling?
- 2.5 US Regulations
- 2.5.1 Obtaining FDA Approval: NDAs and ANDAs
- 2.5.2 The Hatch-Waxman Act: Promotion of Generic Drugs
- 2.5.3 The Hatch-Waxman Act: Incentives for the Branded Industry
- 2.5.4 Consequences of the Hatch-Waxman Act
- 2.5.5 Me First: Timing as a Key Factor
- 2.6 European Regulations
- 2.6.1 Generics Entry into the European Markets
- 2.6.2 Further Protection of Branded Products in the European Market
- 2.6.3 Variations Between European Countries
- 2.6.4 Moving Towards Standardisation
- 2.6.5 The 8+2+1 Rule
- 2.7 Japanese Regulations
- 2.8 Compulsory Licensing
- 2.9 Generic Drugs: An Overview
3 Generic Products World Market Forecast 2009-2024
- 3.1 Generic Products Versus Branded Pharmaceuticals
- 3.2 Sales Forecast 2009-2024
- 3.3 Blockbuster Patent Expiries: The Fall of Giants
- 3.4 Implications of the Current Financial Climate
- 3.5 Key Patent Expiries: An Overview 2009-2014
- 3.5.1 Expected Key Patent Expiries in 2009
- 3.5.2 Expected Key Patent Expiries in 2010
- 3.5.3 Expected Key Patent Expiries in 2011
- 3.5.4 Expected Key Patent Expiries in 2012
- 3.5.5 Expected Key Patent Expiries in 2013
- 3.5.6 Expected Key Patent Expiries in 2014
- 3.5.7 Expected Key Patent Expiries 2009-2014: A Summary
- 3.6 Big Pharma Enters the Generics Market
- 3.7 Major Geographical Markets
- 3.7.1 A Shift in Market Share?
- 3.8 Key Therapeutic Areas
4 The US Generics Market 2009-2024
- 4.1 Analysis of the Current Market
- 4.2 Sales for the US Generics Market: Forecast 2009-2024
- 4.3 Is Market Penetration Reaching a Saturation Point?
- 4.4 Growing Consumer Acceptance of Generic Medicines
- 4.5 The ANDA Backlog
- 4.6 Declining Market Share
- 4.7 Regulatory Environment
- 4.8 Concluding Remarks
5 The European Generics Market 2009-2024
- 5.1 Analysis of the Current Generics Market in Europe
- 5.2 Sales for the European Generics Market: Forecast 2009-2024
- 5.2.1 The Generics Market Varies Within the EU
- 5.2.2 Pricing and Reimbursement
- 5.2.3 Key Challenges to Generic Medicines in Europe
- 5.3 The German Generics Market
- 5.3.1 Sales for the German Generics Market: Forecast 2009-2024
- 5.3.2 High Public Acceptance of Generic Products
- 5.3.3 "Aut Idem" Regulations Encourage Generics Substitution
- 5.3.4 The Future of the German Generics Market
- 5.4 The French Generics Market
- 5.4.1 Sales for the French Generics Market: Forecast 2009-2024
- 5.4.2 The Future of the French Generics Market
- 5.5 The UK Generics Market
- 5.5.1 Sales for the UK Generics Market: Forecast 2009-2024
- 5.5.2 Generics Prescribing Due to Increasing Cost Pressures
- 5.5.3 Reducing Generics Prices: the Drug Tariff System
- 5.5.4 The Increasing Role of Pharmacists
- 5.5.5 Easy Entry, Strong Price Competition
- 5.5.6 The Future of the UK Generics Market
- 5.6 The Spanish Generics Market
- 5.6.1 Sales for the Spanish Generics Market: Forecast 2009-2024
- 5.6.2 Low Price Differences Between Generic and Originator Drugs
- 5.6.3 Prescribing Practices are Limiting Growth
- 5.6.4 The Future of the Spanish Generics Market
- 5.7 The Italian Generics Market
- 5.7.1 Sales for the Italian Generics Market: Forecast 2009-2024
- 5.7.2 Steps Towards Higher Generics Penetration
- 5.7.3 Intellectual Property in Italy
- 5.8 Concluding Remarks
6 The Japanese Generics Market 2009-2024
- 6.1 Analysis of the Current Market
- 6.2 Sales for the Japanese Generics Market: Forecast 2009-2024
- 6.3 The Regulatory Environment
- 6.3.1 Boosting Generic Products
- 6.4 Prescribers' Attitude is a Major Obstacle
- 6.5 Mergers and Acquisitions
- 6.6 Concluding Remarks
7 Emerging Generics Markets 2009-2024
- 7.1 Increased Economic Power
- 7.2 India
- 7.2.1 Sales for the Indian Generics Market: Forecast 2009-2024
- 7.2.2 India' s Patent Law
- 7.2.3 Section 3(d) of the Indian Patents Act
- 7.2.4 International Success of India' s Pharmaceutical Industry
- 7.3 China
- 7.3.1 Sales for the Chinese Generics Market: Forecast 2009-2024
- 7.3.2 Pricing and Reimbursement
- 7.3.3 Patent Law
- 7.3.4 China or India?
- 7.4 Russian Federation
- 7.4.1 Sales for the Russian Federation Generics Market: Forecast
2009-2024
- 7.4.2 Imported Versus Domestic Pharmaceuticals
- 7.4.3 Pharmaceutical Distribution and Financial Strains
- 7.4.4 Per Capita Consumption Rates are Low
- 7.4.5 Prospects for the Russian Market
- 7.5 Concluding Remarks
8 Leading Generics Companies
- 8.1 Teva Pharmaceutical Industries
- 8.1.1 World Sales for Teva in 2008
- 8.1.2 Geographical Breakdown of Sales
- 8.2 Novartis' Sandoz
- 8.2.1 Sales and Presence in the Major Geographical Regions
- 8.3 Mylan Inc
- 8.3.1 Acquisitions
- 8.3.2 International Presence
- 8.4 Watson Pharmaceuticals
- 8.4.1 International Presence
- 8.5 Ratiopharm
- 8.5.1 International Presence
- 8.5.2 The Future for Ratiopharm
9 Market Drivers and Restraints
- 9.1 Primary Drivers
- 9.1.1 The Ageing Population: Opportunities for Growth
- 9.1.2 Healthcare on a Budget
- 9.1.3 Generics Penetration Rates in the Developed World
- 9.1.4 Opportunities in the Emerging Markets
- 9.1.5 Supergenerics
- 9.1.6 Generics Companies: Bulking Up
- 9.1.7 Mergers and Acquisitions
- 9.2 Primary Restraints
- 9.2.1 Dependency on Branded Pharmaceuticals
- 9.2.2 Branded Resistance
- 9.2.3 Biogenerics: Not as Easy as Small Molecules
- 9.2.4 Rigid Intellectual Property Laws
10 Expert Opinion
- 10.1 Charlie Mayr, GPhA
- 10.1.1 The Value of the Generics Market
- 10.1.2 Main Challenges for the US Generics Market
- 10.1.3 On Authorized Generic Products
- 10.1.4 On Biogeneric Products
11 Conclusions
- 11.1 Generics Penetration Reaching Maturity?
- 11.2 Patent Expiries: A Key Growth Driver
- 11.3 Dependence on the Brands: A Thinning Pipeline
- 11.4 Price Declines and Volume Increases
- 11.5 Summary of Forecasts
- 11.6 Concluding Remarks
List of Tables
- Table 3.1 Generics World Market, Sales ($bn) and Growth (%), 2008-2014,
2019, 2024
- Table 3.2 Major Patent Expiries by World Sales ($bn), 2009-2014
- Table 3.3 Patent Expiries by Number, 2009-2014
- Table 3.4 Expected Key Patent Expiries, 2009
- Table 3.5 Expected Key Patent Expiries, 2010
- Table 3.6 Expected Key Patent Expiries, 2011
- Table 3.7 Expected Key Patent Expiries, 2012
- Table 3.8 Expected Key Patent Expiries, 2013
- Table 3.9 Expected Key Patent Expiries, 2014
- Table 3.10 Major Generics Markets, Market Share (%), 2008
- Table 3.11 Major Therapeutic Areas in the Generics Market, Market Share
(%), 2008
- Table 4.1 US Generics Market, Sales ($bn) and Growth (%), 2008 -2014,
2019, 2024
- Table 5.1 European Generics Market, Sales ($bn) and Growth (%), 2008-2014,
2019, 2024
- Table 5.2 Key Challenges Affecting EU Generics Markets
- Table 5.3 German Generics Market, Sales ($bn) and Growth (%), 2008-2014,
2019, 2024
- Table 5.4 French Generics Market, Sales ($bn) and Growth (%), 2008-2014,
2019, 2024
- Table 5.5 UK Generics Market, Sales ($bn) and Growth (%), 2008-2014, 2019,
2024
- Table 5.6 UK Department of Health Classes of Generic Drugs
- Table 5.7 Spanish Generics Market, Sales ($bn) and Growth (%), 2008-2014,
2019, 2024
- Table 5.8 Italian Generics Market, Sales ($bn) and Growth (%), 2008-2014,
2019, 2024
- Table 6.1 Japanese Generics Market, Sales ($bn) and Growth (%), 2008-2014,
2019, 2024
- Table 7.1 Indian Generics Market, Sales ($bn) and Growth (%), 2008-2014,
2019, 2024
- Table 7.2 Chinese Generics Market, Sales ($bn) and Growth (%), 2008-2014,
2019, 2024
- Table 7.3 Russian Generics Market, Sales ($bn) and Growth (%), 2008-2014,
2019, 2024
- Table 8.1 Leading Companies in the Generics Market, World Sales ($bn) and
Market Share (%), 2008
- Table 8.2 Teva World Sales ($bn) by Therapeutic Class
- Table 8.3 Teva Top Selling Products, World Sales ($bn), 2008
- Table 8.4 Teva Sales ($bn) by Geographical Region, 2008
- Table 8.5 Mylan World Sales ($bn) by Therapeutic Class, 2008
- Table 8.6 Mylan Inc Sales Share (%) by Geographical Region, 2008
- Table 8.7 Watson Pharmaceuticals World Sales ($bn) by Therapeutic Class,
2008
- Table 8.8 Ratiopharm World Sales ($bn) by Therapeutic Class, 2008
- Table 8.9 Ratiopharm Sales ($m) and Sales Share (%) by Geographical
Region, 2008
- Table 9.1 SWOT Analysis for The World Generics Market, 2009
List of Figures
- Figure 3.1 Generic Products Versus Branded Pharmaceuticals, Market Share
(%), 2008
- Figure 3.2 Generics World Market Sales ($bn), 2008-2024
- Figure 3.3 Expected Key Patent Expiries by Sales ($bn), 2009-2014
- Figure 3.4 Major Generics Markets, Market Share (%), 2008
- Figure 3.5 Key Generics Markets, Market Share (%), 2009
- Figure 3.6 Key Generics Markets, Market Share (%), 2014
- Figure 3.7 Key Generics Markets, Market Share (%), 2019
- Figure 3.8 Key Generics Markets, Market Share (%), 2024
- Figure 3.9 Major Therapeutic Areas in the Generics Market, Market Share
(%), 2008
- Figure 4.1 US Generics Market Sales ($bn), 2008-2024
- Figure 5.1 European Generics Market Sales ($bn), 2008-2024
- Figure 5.2 German Generics Market Sales ($bn), 2008-2024
- Figure 5.3 French Generics Market Sales ($bn), 2008-2024
- Figure 5.4 UK Generics Market Sales ($bn), 2008-2024
- Figure 5.5 Spanish Generics Market Sales ($bn), 2008-2024
- Figure 5.6 Italian Generics Market Sales ($bn), 2008-2024
- Figure 6.1 Japanese Generics Market Sales ($bn), 2008-2024
- Figure 7.1 Indian Generics Market, Sales ($bn), 2008-2024
- Figure 7.2 Chinese Generics Market, Sales ($bn), 2008-2024
- Figure 7.3 Russian Generics Market, Sales ($bn), 2008-2024
- Figure 7.4 Chinese, Indian and Russian Generics Markets, Growth (%), 2009,
2014, 2019, 2024
- Figure 7.5 Chinese, Indian and Russian Generics Markets, Market Share (%),
2009, 2014, 2019, 2024
- Figure 8.1 Leading Companies in the Generics Market, Market Share (%), 2008
- Figure 8.2 Teva Sales Share (%) by Geographical Region, 2008
- Figure 8.3 Divisions of Novartis by Sales ($bn), 2008
- Figure 8.4 Mylan Inc Sales Share (%) by Geographical Region, 2008
- Figure 8.5 Ratiopharm Sales Share (%) by Geographical Region, 2008
- Abbott
- Actavis
- Apotex
- Arrow Group (Watson Pharmaceuticals)
- AstraZeneca
- Aurobindo (Pfizer)
- Barr Pharmaceuticals (Teva)
- Bayer
- Blue Cross Blue Shield Association
- Boehringer Ingelheim
- Bristol-Myers Squibb
- British Generics Manufacturers Association (BGMA)
- Centers for Medicare and Medicaid Services
- Daiichi-Sankyo
- Dr. Reddy' s Laboratories
- Eisai
- Eli Lilly
- European Generic Medicines Association (EGA)
- European Medicines Agency (EMEA)
- Food and Drug Administration (FDA)
- Generic Pharmaceuticals Association (GPhA)
- German Pharmacy Association
- GlaxoSmithKline
- Greenstone (Pfizer)
- Hospira
- International Federation of Pharmaceutical Manufacturers Associations
- Italian Generics Association (Assogenerici)
- Johnson & Johnson
- Kowa Company Ltd
- Lundbeck
- Merck & Co
- Millennium Pharmaceuticals (Takeda)
- Mylan Inc
- National Health Service (NHS)
- Novartis
- Otsuka
- Pfizer
- Procter & Gamble
- Purdue/Mundipharma
- Ranbaxy
- Ratiopharm
- Roche
- Sandoz (Novartis)
- Sanofi-Aventis
- Schering-Plough
- Sciele Pharma (Shionogi)
- Shionogi
- Shire
- Spanish Association of Generic Medicines
- Stada Healthcare
- Sun Pharma
- Takeda
- Teva Pharmaceutical Industries
- UCB
- Watson Pharmaceuticals
- World Trade Organization (WTO)
- Wyeth
|
